The company's platform is based on a CD180 platform technology that delivers antigens capable of evoking protective immunity to a receptor expressed on two major classes of cells that program immune responses. Their Antigen-Specific Immune Accelerants (ASIA) are potent, specific, and durable, with broad applications across infectious disease and oncology, providing medical professionals with a platform that can plug-and-play with multiple cancer or viral antigens. Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of their CD180 platform technology.